相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
Ibai Goicoechea et al.
BLOOD (2021)
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
Jill Corre et al.
BLOOD (2021)
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma
Stefania Oliva et al.
ANNALS OF HEMATOLOGY (2021)
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Irene M. Ghobrial et al.
CLINICAL CANCER RESEARCH (2020)
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Herve Avet-Loiseau et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
Sarah Goldman-Mazur et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
The microenvironment in myeloma
Oliver C. Lomas et al.
CURRENT OPINION IN ONCOLOGY (2020)
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
Jill Corre et al.
HAEMATOLOGICA (2020)
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
Roberto Mina et al.
BLOOD CANCER JOURNAL (2020)
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial
Rowan Kuiper et al.
BLOOD ADVANCES (2020)
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
Elena Zamagni et al.
JOURNAL OF CLINICAL MEDICINE (2020)
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Brian A. Walker et al.
LEUKEMIA (2019)
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
Anjan Thakurta et al.
BLOOD (2019)
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
Leo Rasche et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Aurore Perrot et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)
Anna Kalff et al.
LEUKEMIA & LYMPHOMA (2019)
Multiple myeloma clonal evolution in homogeneously treated patients
Jill Corre et al.
LEUKEMIA (2018)
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Guy Ledergor et al.
NATURE MEDICINE (2018)
Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma
Cody Ashby et al.
BLOOD (2018)
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow
Celine Mazzotti et al.
BLOOD ADVANCES (2018)
Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma
S. Mithraprabhu et al.
LEUKEMIA (2017)
Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia
Lili Wang et al.
GENOME RESEARCH (2017)
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
O. Landgren et al.
JOURNAL OF INTERNAL MEDICINE (2017)
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
L. Rasche et al.
NATURE COMMUNICATIONS (2017)
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
Olena Kis et al.
NATURE COMMUNICATIONS (2017)
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
M. Chin et al.
BLOOD CANCER JOURNAL (2017)
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
C. Pawlyn et al.
BLOOD CANCER JOURNAL (2017)
Tumor Evolution as a Therapeutic Target
Nabil Amirouchene-Angelozzi et al.
CANCER DISCOVERY (2017)
MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)pos multiple myeloma indicate poor prognosis
Feng Li et al.
ONCOTARGET (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
Evolutionary biology of high-risk multiple myeloma
Charlotte Pawlyn et al.
NATURE REVIEWS CANCER (2017)
Prognostic role of circulating exosomal miRNAs in multiple myeloma
Salomon Manier et al.
BLOOD (2017)
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
O. Landgren et al.
BONE MARROW TRANSPLANTATION (2016)
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
Benjamin Hebraud et al.
BLOOD (2015)
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Marie-Lorraine Chretien et al.
BLOOD (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine
Jerome Moreaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
Sridurga Mithraprabhu et al.
EPIGENETICS (2014)
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
B. Hebraud et al.
LEUKEMIA (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
The role of epigenetics in the biology of multiple myeloma
K. Dimopoulos et al.
BLOOD CANCER JOURNAL (2014)
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
Martin F. Kaiser et al.
BLOOD (2013)
Aberrant microRNA expression in multiple myeloma
Konstantinos Dimopoulos et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
K. Giannopoulos et al.
BRITISH JOURNAL OF CANCER (2012)
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity
Amir A. Toor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma
Karthick Raja Muthu Raja et al.
PLOS ONE (2012)
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Herve Avet-Loiseau et al.
BLOOD (2011)
Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients
Florence Magrangeas et al.
BLOOD (2011)
1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma
H. Chang et al.
BONE MARROW TRANSPLANTATION (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
R. Fonseca et al.
LEUKEMIA (2006)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
R Fonseca et al.
BLOOD (2003)
分享论文
